登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 18 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 18
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
- 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
- 研究中心江苏省苏北人民医院Northern Jiangsu People's Hospital扬州医院页面
- 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
- 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
- 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
- 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
- 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
- 研究中心空军军医大学唐都医院Tangdu Hospital西安医院页面
- 研究中心中南大学湘雅三医院Third Xiangya Hospital长沙医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面
- 研究中心中山市人民医院Zhongshan City People's Hospital中山医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07367529,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 9
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(9 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Lung cancer confirmed by histology or cytology;
入选标准第 14 条
Willing to provide qualified tumor tissue samples for immunohistochemical and amplification testing, unless the participant has no eligible archived specimens and is unsuitable or refuses re-biopsy;
入选标准第 15 条
History of or concurrent other malignancies, except for: other malignancies treated with surgery alone and achieving ≥5 years of disease-free survival (DFS); or cured carcinoma in situ of cervix, non-melanoma skin cancer, or superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading basement membrane)].
排除标准第 1 条
Cardiac dysfunction ≥New York Heart Association (NYHA) class II or Left Ventricular Ejection Fractions (LVEF) <50% by echocardiography;
排除标准第 14 条
Chemotherapy, immunotherapy, or small-molecule targeted therapy within 3 weeks prior to first dose or within 5 half-lives (whichever shorter); prior local radiotherapy allowed if: completed >4 weeks (>2 weeks for brain) before study treatment, and target lesions are outside radiation field or show progression within field;
排除标准第 27 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
入选标准第 3 条
Hemoglobin (HGB) ≥ 90 g/L;
入选标准第 7 条
Absolute neutrophil count (NEUT) ≥ 1.5×10⁹/L;
入选标准第 8 条
Platelet count (PLT) ≥ 90×10⁹/L;
入选标准第 9 条
Total bilirubin (TBIL) ≤ 1.5×Upper Limit of Normal (ULN);
入选标准第 10 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (≤ 5×ULN if liver metastases are present);
入选标准第 11 条
Serum creatinine (CR) ≤ 1.3×ULN or creatinine clearance rate (CCR) ≥ 50 mL/min;
入选标准第 12 条
Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy within the past 2 weeks);
入选标准第 13 条
Active viral hepatitis with poor control, except: hepatitis B surface antigen (HBsAg)-positive participants with HepatitisBvirus Deoxyribonucleic acid (HBV DNA) <500 IU/mL (2500 copies/mL) who agree to receive anti-HBV therapy throughout study; or hepatitis C virus (HCV)-infected participants (Hepatitis C Virus Antibody or Ribonucleic Acid positive) with hepatitis C virus Ribonucleic Acid (HCV RNA) ≤ULN continuing approved antiviral therapy.
排除标准第 7 条
Prior EGFR/c-Met-targeted Monoclonal Antibody (mAbs)/bispecifics with: ≥grade 4 toxicity, permanent discontinuation due to toxicity, ≥grade 3 infusion reactions, or ≥grade 3 myalgia.
排除标准第 34 条
At least one measurable lesion according to RECIST v1.1 criteria;
入选标准第 5 条
Immunodeficiency including HIV positivity or other acquired/congenital immunodeficiency diseases.
排除标准第 22 条
Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion, with a negative serum or urine pregnancy test within 7 days before enrollment; male participants must agree to use effective contraception during the study and for 6 months after study completion (see Section 5.5 for details).
入选标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07367529,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance; Age between 18 and 75 years (calculated based on the date of signing the informed consent form); Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; Expected survival greater than 12 weeks; At least one measurable lesion according to RECIST v1.1 criteria; Laboratory test results meeting the following criteria (no blood transfusion within 14 days or hematopoietic growth factor administration within 7 days prior to screening): Hemoglobin (HGB) ≥ 90 g/L; Absolute neutrophil count (NEUT) ≥ 1.5×10⁹/L; Platelet count (PLT) ≥ 90×10⁹/L; Total bilirubin (TBIL) ≤ 1.5×Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (≤ 5×ULN if liver metastases are present); Serum creatinine (CR) ≤ 1.3×ULN or creatinine clearance rate (CCR) ≥ 50 mL/min; Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy within the past 2 weeks); Lung cancer confirmed by histology or cytology; Willing to provide qualified tumor tissue samples for immunohistochemical and amplification testing, unless the participant has no eligible archived specimens and is unsuitable or refuses re-biopsy; Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion, with a negative serum or urine pregnancy test within 7 days before enrollment; male participants must agree to use effective contraception during the study and for 6 months after study completion (see Section 5.5 for details).排除标准:Exclusion Criteria:
History of or concurrent other malignancies, except for: other malignancies treated with surgery alone and achieving ≥5 years of disease-free survival (DFS); or cured carcinoma in situ of cervix, non-melanoma skin cancer, or superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading basement membrane)]. Diseases affecting intravenous injection or blood sampling. Adverse reactions from prior therapies not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grade ≤1, except for: grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant asymptomatic grade 2 laboratory abnormalities, hypothyroidism stabilized with hormone replacement, or other toxicities judged by investigator as non-safety risks. Major surgery (Grade 3 or above per National Surgical Classification Catalog 2022), significant traumatic injury within 4 weeks prior to first dose, planned major surgery during study (except protocol-specified procedures), or presence of unhealed wounds/fractures. Any bleeding or hemorrhagic events ≥CTCAE grade 3 within 4 weeks prior to first dose. Arterial/venous thromboembolic events within 6 months prior to first dose, including: cerebrovascular accidents (including transient ischemic attack (TIA), excluding lacunar infarction), deep vein thrombosis, or pulmonary embolism (implantable venous port- or catheter-related thrombosis or superficial venous thrombosis not considered "severe" thromboembolism). Active viral hepatitis with poor control, except: hepatitis B surface antigen (HBsAg)-positive participants with HepatitisBvirus Deoxyribonucleic acid (HBV DNA) <500 IU/mL (2500 copies/mL) who agree to receive anti-HBV therapy throughout study; or hepatitis C virus (HCV)-infected participants (Hepatitis C Virus Antibody or Ribonucleic Acid positive) with hepatitis C virus Ribonucleic Acid (HCV RNA) ≤ULN continuing approved antiviral therapy. Active syphilis requiring treatment. Active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced/radiation pneumonitis requiring treatment, clinically significant active pneumonia, history of interstitial lung disease (ILD) requiring treatment, or current ILD. History of psychotropic drug abuse or mental disorders. Prior or planned allogeneic bone marrow or solid organ transplantation. History of hepatic encephalopathy. Significant cardiovascular diseases including: Cardiac dysfunction ≥New York Heart Association (NYHA) class II or Left Ventricular Ejection Fractions (LVEF) <50% by echocardiography; Clinically significant ventricular arrhythmia history (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or arrhythmias requiring continuous antiarrhythmic therapy (participants with stable atrial fibrillation controlled solely by β-blockers may be included after investigator assessment); Unstable angina; Myocardial infarction within 12 months; Cardio contraction time (QTc) >450ms (male) or >470ms (female) (if abnormal, measure three times at ≥2-minute intervals and average; corrected by Fridericia or Bazett method); Congenital long QT syndrome or family history. Active or uncontrolled severe infection (≥CTCAE grade 2). Renal failure requiring hemodialysis or peritoneal dialysis. Immunodeficiency including HIV positivity or other acquired/congenital immunodeficiency diseases. Uncontrolled autoimmune diseases requiring immunosuppressants or systemic corticosteroids (>10mg prednisone/day equivalent) within 7 days prior to first dose. Epilepsy requiring treatment. Poorly controlled diabetes (fasting blood glucose >10mmol/L). Tumor-related conditions and treatments: Chemotherapy, immunotherapy, or small-molecule targeted therapy within 3 weeks prior to first dose or within 5 half-lives (whichever shorter); prior local radiotherapy allowed if: completed >4 weeks (>2 weeks for brain) before study treatment, and target lesions are outside radiation field or show progression within field; National Medical Products Administration (NMPA)-approved traditional Chinese medicines with antitumor indications within 1 week prior to first dose; Tumor invading major vessels or judged likely to cause fatal hemorrhage; Uncontrolled effusions/ascites requiring recurrent drainage; Spinal cord compression, leptomeningeal metastases, or brain metastases with symptoms controlled <4 weeks, or requiring steroids/dehydrating agents within 2 weeks before treatment. Known hypersensitivity to study drug or excipients. Prior treatment with: Epidermal Growth Factor Receptor/cellular-mesenchymal epithelial transition factor (EGFR/c-Met)-targeted antibody-drug conjugates (ADCs); or topoisomerase I inhibitors (Non-Small Cell Lung Cancer only) or topoisomerase I inhibitor-based ADCs. Prior EGFR/c-Met-targeted Monoclonal Antibody (mAbs)/bispecifics with: ≥grade 4 toxicity, permanent discontinuation due to toxicity, ≥grade 3 infusion reactions, or ≥grade 3 myalgia. Participation in other antitumor clinical trials within 4 weeks prior to first dose. Other conditions judged by investigator to jeopardize participant safety or study completion.
引自 ClinicalTrials.gov, NCT07367529, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07367529,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。